Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-03-21
Butterfly Network, Inc.
Butterfly Network develops handheld ultrasound probes, cloud workflow software, and partner licensing tools for clinical imaging.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable imaging with platform upside, execution gates
The bull case is not just more handheld ultrasound units. The real prize is turning a differentiated probe into recurring workflow, governance, and partner revenue before larger imaging vendors compress that opportunity.

Analysis

Thesis
Butterfly can grow into a larger medtech-software hybrid if it turns its ultrasound chip into a control plane for handheld imaging, enterprise governance, and partner licensing; the upside is real, but durable value capture still depends on proving repeatable software and embedded revenue beyond core probe sales.
Last Economy Alignment
Cheaper cognition should widen handheld ultrasound use, and Butterfly owns real chip, workflow, and trust control points. The ceiling is that larger imaging vendors can still make its software feel optional unless governance and licensing mature into must-have layers.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.0x (from 5 most recent analyses)
Reasoning
The stock can earn a better outcome than a pure device name if software, governance, and licensing become a meaningful share of mix, but it is still too early for a full software-style rerating. I underwrite a middle path: solid core handheld growth, real contribution from newer channels, margin improvement from higher-value mix, and a persistent discount to the best recurring-revenue healthcare platforms.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The upside case depends on Butterfly proving it is more than a clever probe company. The key risks are slower health-system adoption, lumpy embedded revenue, enterprise trust/compliance gates, and larger imaging vendors using broader contracts and service coverage to cap software attach and pricing power.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.42
They own a real control point: the ultrasound chip and the handheld probe, and AI can make bedside imaging easier to use and more widely adopted. The risk is that bigger vendors can bundle similar tools and make Butterfly's software feel optional unless its trust and workflow layers become the standard route through the system.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case